Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not

Más betegség

• Extracellular plasma cell disease, central invasion of myeloma, plasma cell leukemia
• History of other malignant tumors within the past 5 years
• Patients with HIV, active tuberculosis, clinically active hepatitis A, B, or C
• Other serious condition that may restrict patients from continuing treatment (such as advanced infection, uncontrolled diabetes, severe cardiac insufficiency, or angina pectoris)
• General condition not suitable for chemotherapy
• Suffering from other serious organic diseases and mental disorders.

Egyéb

• Two or more high-risk cytogenetic abnormalities, including del (17p), t (4; 14), t (14; 16), del (1p), amp (1q). Fluorescence in situ hybridization was used to analyze CD138 positive sorted cells, with cut off value of 15% for translocation, 10% for deletion, and amp (1q) of 20%.
• Pregnant or lactating women

• Newly diagnosed multiple myeloma according to the criteria of International Working Group of Myeloma
• Age ranges from 18-70 years old
• Achieved MRD negativity and at least very good partial response in clinical response after 4-6 courses of induction therapy. MRD is measured by MRD by multicolor flow with a sensitivity of 10-5.
• At enrollment, score of Eastern Cooperative Oncology Group (ECOG) should be 0-2.
• Organ function requirement: Blood bilirubin ≤ 2mg/dL (35 μ mol/L), Alanine aminotransferase/Aspartate aminotransferase below 2 times the upper limit of normal value, Creatinine clearance rate (Ccr) ≥ 30ml/min and Cardiac ejection fraction ≥50%.
• Expected survival more than 3 months.